Sangamo Therapeutics Inc [NASDAQ: SGMO] gained 23695221% on the last trading session, reaching $6690000.0 price per share at the time.
Sangamo Therapeutics Inc represents 245.40 million in outstanding shares, while the company has a total market value of $126.08 million with the latest information. SGMO stock price has been found in the range of $0.4396 to $0.5398.
If compared to the average trading volume of 6.69M shares, SGMO reached a trading volume of 23695221 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Sangamo Therapeutics Inc [SGMO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SGMO shares is $4.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGMO stock is a recommendation set at 1.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Sangamo Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 10, 2024, representing the official price target for Sangamo Therapeutics Inc stock. Previously, the target price had yet another drop from $6 to $2, while RBC Capital Mkts kept a Sector Perform rating on SGMO stock. On April 28, 2023, analysts decreased their price target for SGMO shares from 5 to 1.50.
The Price to Book ratio for the last quarter was 23.60, with the Price to Cash per share for the same quarter was set at 0.10.
Trading performance analysis for SGMO stock
Sangamo Therapeutics Inc [SGMO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.76. With this latest performance, SGMO shares gained by 3.90% in over the last four-week period, additionally sinking by -78.14% over the last 6 months – not to mention a drop of -49.63% in the past year of trading.
Sangamo Therapeutics Inc [SGMO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Sangamo Therapeutics Inc [SGMO] shares currently have an operating margin of -128.52% and a Gross Margin at 86.26%. Sangamo Therapeutics Inc’s Net Margin is presently recorded at -126.63%.
Return on Equity for this stock declined to -75.06%, with Return on Assets sitting at -75.06%.
Sangamo Therapeutics Inc [SGMO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SGMO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sangamo Therapeutics Inc go to 20.66%.
An analysis of Institutional ownership at Sangamo Therapeutics Inc [SGMO]
There are presently around $22.34%, or 23.00% of SGMO stock, in the hands of institutional investors. The top three institutional holders of SGMO stocks are: WASATCH ADVISORS LP with ownership of 20.09 million shares, which is approximately 9.8509%. ARMISTICE CAPITAL, LLC, holding 14.06 million shares of the stock with an approximate value of $$5.04 million in SGMO stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$4.26 million in SGMO stock with ownership which is approximately 5.8341%.
